Liquid Biopsy Market
Report ID: SQMIG35J2060
Report ID: SQMIG35J2060
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35J2060 |
Region:
Global |
Published Date: August, 2025
Pages:
177
|Tables:
199
|Figures:
75
Global Liquid Biopsy Market size was valued at USD 4.98 Billion in 2024 and is poised to grow from USD 5.51 Billion in 2025 to USD 12.43 Billion by 2033, growing at a CAGR of 10.7% in the forecast period (2026–2033).
The liquid biopsy market is witnessing significant momentum as healthcare systems increasingly prioritize non-invasive diagnostic tools for cancer detection and monitoring. With the shift toward precision medicine, liquid biopsy has emerged as a valuable alternative to traditional tissue biopsies, offering quicker turnaround times, reduced patient discomfort, and the ability to monitor tumor progression in real time.
The market is characterized by ongoing technological advancements, particularly in ctDNA and CTC detection methods, along with integration of AI and next generation sequencing to improve sensitivity and specificity. Pharmaceutical companies and diagnostic labs are actively collaborating to develop companion diagnostics and multi-cancer detection platforms.
Regulatory agencies across major regions are showing growing support through updated guidelines and reimbursement policies, further enhancing adoption. As clinical validation continues to expand, liquid biopsy is poised to play a central role in the future of oncology diagnostics and personalized treatment pathways.
How is AI Enhancing Early Cancer Detection Through Liquid Biopsy?
In 2024, artificial intelligence will revolutionize liquid biopsy by dramatically improving the detection and analysis of circulating biomarkers such as cell-free DNA (cfDNA), circulating tumor cells (CTCs), and protein markers. Advanced AI/ML algorithms are now capable of analyzing complex molecular patterns and frag entomic features, enabling more precise identification of cancer-related signals from blood samples. This enhances early detection, recurrence prediction, and treatment monitoring capabilities.
Market snapshot - 2026-2033
Global Market Size
USD 4.47 Billion
Largest Segment
Assay Kits
Fastest Growth
Services
Growth Rate
10.7% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global liquid biopsy market is segmented into product, circulating biomarker, technology, application, clinical application, sample type, end user and region. Based on product, the market is segmented into assay kits, instruments and services. Based on circulating biomarkers, the market is segmented into circulating tumor cells, circulating tumor DNA, cell-free DNA, extracellular vesicles and other circulating biomarkers. Based on technology, the market is segmented into multi-gene parallel analysis using NGS and single-gene analysis using PCR. Based on application, the market is segmented into cancer applications and non-cancer applications. Based on clinical application, the market is segmented into therapy selection, treatment monitoring, early cancer screening and recurrence monitoring. Based on sample type, the market is segmented into blood samples and other sample types. Based on end user, the market is segmented into reference laboratories, hospitals & physician laboratories, academic & research centers and other end users. Based on region, the market is segmented into North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa.
How are Assay Kits Supporting Precision Oncology?
As per the global liquid biopsy market outlook, assay kits hold the dominant position in the market, primarily because they form the backbone of most diagnostic procedures involving ctDNA, CTCs, and exosomal RNA. These kits are widely used in hospitals, diagnostic laboratories, and research centers due to their reliability, standardized protocols, and compatibility with existing workflows. Their consistent demand is further supported by regulatory approvals for clinical use and their role in cancer screening, therapy selection, and recurrence monitoring. As the adoption of precision oncology grows, so does the reliance on these validated assay kits, making them the most commercially successful product segment.
As per global liquid biopsy market forecast, the services segment is experiencing the fastest growth, driven by the increasing complexity of liquid biopsy testing and the demand for specialized expertise in genomic analysis. Many healthcare providers and pharmaceutical companies are outsourcing liquid biopsy testing to third-party labs, bioinformatics companies, and CROs that offer end-to-end solutions from sample processing to data interpretation. As liquid biopsy evolves beyond single biomarker detection into comprehensive genomic profiling and AI-assisted diagnostics, service providers are stepping in to deliver scalable, high-throughput, and regulatory-compliant testing services.
How do Cancer Diagnostics Benefit from Liquid Biopsy Adoption?
Cancer applications are the dominant segment in the liquid biopsy market. These include early cancer detection, treatment selection, therapy monitoring, and recurrence surveillance across a variety of cancers such as lung, breast, colorectal, and prostate cancer. The dominance of this segment is driven by the high global burden of cancer, increasing awareness of precision oncology, and the growing preference for non-invasive alternatives to tissue biopsy. Moreover, regulatory approvals for ctDNA-based cancer diagnostics and strong adoption in oncology clinical trials continue to strengthen the segment’s market share.
As per the global liquid biopsy market analysis, non-cancer applications are emerging as the fastest-growing segment. These include applications in organ transplant monitoring, prenatal genetic testing, and infectious disease diagnostics. The growing use of liquid biopsy in detecting organ rejection through donor-derived cell-free DNA (dd-cfDNA) and non-invasive prenatal testing (NIPT) for chromosomal abnormalities is driving this growth. Increasing research and technological advancements are expanding the utility of liquid biopsy technologies beyond oncology, unlocking new diagnostic possibilities and revenue streams.
To get detailed segments analysis, Request a Free Sample Report
How is the Liquid Biopsy Market Progressing in North America?
As per regional outlook, North America remains the global frontrunner in liquid biopsy adoption due to a combination of advanced diagnostic infrastructure, early clinical adoption, and strong research funding. The high prevalence of cancer, particularly lung, breast, and colorectal, has pushed the demand for early detection and minimally invasive diagnostic tools. In addition, the regulatory environment especially in the U.S. is increasingly supportive of liquid biopsy innovations, with the FDA actively granting breakthrough device designations and accelerating review processes for novel tests. The presence of market leaders and a vibrant startup ecosystem further accelerates commercialization and adoption.
Liquid Biopsy Market in the U.S.
The United States commands the largest liquid biopsy market share, attributed to its highly developed healthcare system, favorable reimbursement scenarios, and a robust pipeline of liquid biopsy products. Companies like Guardant Health, Exact Sciences, and Natera continue to introduce advanced ctDNA, cfDNA, and exosome-based assays for early detection and recurrence monitoring. The growing interest in multi-cancer early detection (MCED) is also fueling demand, alongside government-backed cancer moonshot initiatives that prioritize innovation in early diagnostics.
Liquid Biopsy Market in Canada
As per regional outlook, in Canada, the liquid biopsy market is growing steadily, supported by regional genomics programs, academic collaborations, and increased access to advanced diagnostics in cancer centers. Although adoption is slower than in the U.S., the focus on cost-effective and accessible screening is helping expand the clinical reach of liquid biopsy platforms. Government initiatives under health research funding bodies like CIHR are encouraging pilot studies and population-scale validation efforts.
How is Asia Experiencing Transformation in Liquid Biopsy Adoption?
As per regional outlook, Asia-Pacific is quickly emerging as a hotspot for liquid biopsy innovation, fueled by a rising cancer burden, growing awareness, and enhanced government attention toward personalized medicine. Countries across the region are investing in early cancer detection and genomic surveillance, with a particular focus on gastrointestinal, lung, and liver cancers that are more prevalent in Asian populations. The affordability of new diagnostics and the rise of domestic biotech players are key factors reshaping the market.
Liquid Biopsy Market in Japan
As per industry analysis, Japan has established itself as one of the most advanced diagnostic markets in Asia-Pacific. The Japanese government has integrated precision diagnostics, including liquid biopsy, into national cancer screening programs. Major hospitals and academic research institutions are actively validating liquid biopsy tools, especially for non-small cell lung cancer (NSCLC) and gastrointestinal cancers. Clinical acceptance is high, and several locally approved tests are already reimbursed, further accelerating uptake.
Liquid Biopsy Market in South Korea
South Korea’s biotechnology sector is rapidly evolving, with considerable investments in precision oncology and genetic screening. South Korean companies and university labs are developing high-sensitivity assays for early detection, aided by AI and next-generation sequencing. Government-led initiatives, such as Korea’s Bioeconomy Strategy 2025, support local innovation in liquid biopsy. Lung and stomach cancers, two of the most common in Korea, are the primary focus areas for clinical deployment.
How is Europe Advancing Liquid Biopsy Research and Accessibility?
Europe is a stronghold for clinical validation and research in liquid biopsies. The region emphasizes public–private partnerships, academic collaborations, and EU-funded clinical trials that span multiple countries. European regulatory pathways are more cautious than North America but are increasingly harmonizing to support early diagnostics. Emphasis is placed on cost-effectiveness, population health, and data protection, making Europe a valuable contributor to global liquid biopsy advancements.
Liquid Biopsy Market in Germany
Germany is at the forefront of clinical liquid biopsy application in Europe, with numerous hospitals participating in multicenter studies. The German Cancer Research Center (DKFZ) and national genomics initiatives support precision diagnostics, and the country boasts a dense network of certified cancer centers. Technological integration in labs and access to high-throughput sequencing platforms make Germany an innovation hub for cfDNA and ctDNA-based assays.
Liquid Biopsy Market in the UK
The UK continues to be a pioneer in implementing real-world evidence for liquid biopsy. The National Health Service (NHS), through initiatives like the Genomic Medicine Service, provides structured access to early detection tools, including liquid biopsy. Research efforts by institutions like Cancer Research UK and startups such as Dxcover have strengthened the country’s leadership in early detection and affordable diagnostics using AI and non-sequencing approaches.
Liquid Biopsy Market in Italy
Italy is making strides in expanding the availability of liquid biopsy, particularly through its network of academic hospitals and oncology centers. EU-backed funding and local cancer screening initiatives are encouraging wider clinical trials and validation efforts. Italian researchers are increasingly focused on multi-cancer detection and monitoring of minimal residual disease (MRD), helping to diversify the clinical use cases of liquid biopsy technologies.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Liquid Biopsy Market Drivers
Rising Demand for Non-Invasive Diagnostics
Expansion of Precision Medicine
Liquid Biopsy Market Restraints
Limited Accessibility in Low-Income Regions
Insufficient Clinical Validation Across Cancer Types
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the liquid biopsy industry in 2024 is marked by increasing innovation, strategic partnerships, and a strong focus on expanding applications in early cancer detection and treatment monitoring. Leading players such as Guardant Health, Illumina, Natera, and Exact Sciences continue to dominate through their proprietary technologies and wide diagnostic reach.
As per market strategies, in February 2024, DELFI Diagnostics launched a new fragmentome-based assay called DELFI-TF and entered a strategic research collaboration with Immunocore to assess its effectiveness in monitoring tumor response to immunotherapy.
Startups in the liquid biopsy market are playing a pivotal role in reshaping the landscape of cancer diagnostics through innovation, agility, and technological disruption. These emerging companies focus on developing ultra-sensitive platforms for early cancer detection, treatment response monitoring, and minimal residual disease (MRD) tracking using blood-based assays. Many are leveraging cutting-edge approaches such as fragmentomics, methylation profiling, and AI-driven genomic interpretation to enhance the accuracy and accessibility of liquid biopsy.
Top Player’s Company Profiles
Recent Developments in Liquid Biopsy Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global liquid biopsy market growth, driven by increasing demand for non-invasive cancer diagnostics, advancements in genomic technologies, and the rising prevalence of various cancers worldwide. Liquid biopsies, particularly those using blood samples to detect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes, have gained strong traction due to their ability to provide real-time insights into tumor dynamics without the need for surgical intervention. It has been used in the stratification of the tumor, thereby offering targeted therapy to the cancer. For instance, the FDA approved, in January 2023, the liquid biopsy assay Guardant360 CDx by Guardant Health as a companion diagnostic to diagnose ESR1 mutant breast cancer. Recent inventions, progressions, and expansion in this sector boost liquid biopsy and foster market growth.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 4.98 Billion |
| Market size value in 2033 | USD 12.43 Billion |
| Growth Rate | 10.7% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Liquid Biopsy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Liquid Biopsy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Liquid Biopsy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Liquid Biopsy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
The global liquid biopsy market is projected to grow at a compound annual growth rate (CAGR) of approximately 10.7% through 2032, reflecting rising demand for non-invasive diagnostic solutions and precision oncology.
Liquid biopsy adoption is driven by its non-invasive nature, real-time disease monitoring, and rising demand for early cancer detection and personalized therapies.
Personalized medicine drives the liquid biopsy market by enabling tailored treatments through real-time tumor mutation and drug resistance monitoring.
Next-generation sequencing (NGS) is a cornerstone technology in liquid biopsy diagnostics. It enables comprehensive genomic analysis by detecting circulating tumor DNA (ctDNA) and other molecular alterations in blood samples.
The main applications of liquid biopsy in cancer diagnostics include early detection, treatment selection, and monitoring of minimal residual disease (MRD). These applications are particularly valuable when conventional tissue samples are not accessible or when frequent monitoring is required throughout a patient’s treatment journey.
In liquid biopsy tests, commonly analyzed biomarkers include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and various protein markers such as PSA, CA-19-9, and CA-125. These biomarkers offer critical insights into tumor dynamics and can guide clinical decisions effectively.
The future of liquid biopsy is being shaped by recent innovations like the development of highly sensitive epigenetic ctDNA assays that detect cancer at early stages. Notable partnerships, such as those involving Guardant Health, are also accelerating the adoption and global accessibility of liquid biopsy technologies.
Global Liquid Biopsy Market size was valued at USD 4.98 Billion in 2024 and is poised to grow from USD 5.51 Billion in 2025 to USD 12.43 Billion by 2033, growing at a CAGR of 10.7% in the forecast period (2026–2033).
The competitive landscape of the liquid biopsy industry in 2024 is marked by increasing innovation, strategic partnerships, and a strong focus on expanding applications in early cancer detection and treatment monitoring. Leading players such as Guardant Health, Illumina, Natera, and Exact Sciences continue to dominate through their proprietary technologies and wide diagnostic reach. 'DELFI Diagnostics', 'Citius Pharmaceuticals', 'BioView Ltd. ', 'Guardant Health, Inc.', 'Biocept, Inc.', 'F. Hoffmann-La Roche Ltd.', 'QIAGEN N.V.', 'Illumina, Inc.', 'Thermo Fisher Scientific, Inc.', 'Lucence Health Inc.', 'NeoGenomics Laboratories, Inc.', 'Exact Sciences Corporation', 'Natera, Inc.', 'ANGLE plc', 'GRAIL, LLC'
The global healthcare landscape is steadily shifting toward non-invasive diagnostic alternatives, and liquid biopsy is at the center of this transformation. Traditional tissue biopsies, while effective, come with challenges such as invasiveness, surgical risk, delays in diagnosis, and patient discomfort. In contrast, liquid biopsy offers a minimally invasive approach that analyzes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers from a simple blood or fluid sample. This allows for faster diagnosis, easier sampling in advanced or inoperable tumors, and repeat testing over time to track disease progression or treatment response.
AI Integration in Liquid Biopsy Platforms: Artificial intelligence is emerging as a transformational force in the liquid biopsy market. In 2024, new platforms such as MRD-EDGE and DELFI-Pro demonstrated how AI can enhance diagnostic performance by detecting subtle genomic patterns in cell-free DNA (cfDNA) that would otherwise go unnoticed. These AI tools are capable of analyzing vast datasets rapidly and identifying rare mutations with high precision, thereby reducing false negatives and improving early cancer detection.
How is the Liquid Biopsy Market Progressing in North America?
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
